• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Inotiv Inc. (Amendment)

    9/20/22 9:00:08 AM ET
    $NOTV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $NOTV alert in real time by email
    SC 13D/A 1 tm2226222d1_sc13da.htm SC 13D/A

     

     

     

    United States

    Securities and Exchange Commission

    Washington, D.C. 20549

     

    Schedule 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

    Inotiv, Inc.

     

     

    (Name of Issuer)

     

    Common Shares, no par value per share

     

     

    (Title of Class of Securities)

     

    45783Q100

     

     

    (CUSIP Number)

     

    Jason Carri
    P2 Capital Partners, LLC
    590 Madison Avenue, 25th Floor
    New York, New York 10022
    (212) 508-5500

     

    with copies to:

     

    Andrew Bab, Esq.
    Debevoise & Plimpton LLP
    919 Third Avenue
    New York, New York 10022
    (212) 909-6000

     

     

    (Name, Address and Telephone Number of Person Authorized to Receive
    Notices and Communications)

     

    September 16, 2022

     

     

    (Date of Event which Requires Filing of this Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rules 13d-1(e), 13d-1(f) or 13d-1(g), check the following box. ¨

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 45783Q100

     

    1

    NAME OF REPORTING PERSON.
    P2 Capital Partners, LLC

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
    (a)
    ¨
    (b)
    ¨

     

    3

    SEC USE ONLY

     

    4

    SOURCE OF FUNDS (SEE INSTRUCTIONS)
    SC

     

    5

    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)
    ¨

     

    6

    CITIZENSHIP OR PLACE OF ORGANIZATION
    State of Delaware

     

    NUMBER OF
    SHARES BENEFICIALLY OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    7 SOLE VOTING POWER
    0 shares
     
    8 SHARED VOTING POWER
    715,705 shares
     
    9 SOLE DISPOSITIVE POWER
    0 shares
     
    10 SHARED DISPOSITIVE POWER
    715,705 shares
     
    11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    715,705 shares
     
    12

    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
    x

     

    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11);
    2.8%

     

    14

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
    CO

     

     

     

     

     

    CUSIP No. 45783Q100

     

    1

    NAME OF REPORTING PERSON.
    P2 Capital Master Fund I, L.P.

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
    (a)
    ¨
    (b)
    ¨

     

    3

    SEC USE ONLY

     

    4

    SOURCE OF FUNDS (SEE INSTRUCTIONS)
    SC

     

    5

    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)
    ¨

     

    6

    CITIZENSHIP OR PLACE OF ORGANIZATION
    Cayman Islands, British West Indies

     

    NUMBER OF
    SHARES BENEFICIALLY OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    7 SOLE VOTING POWER
    715,705 shares
      
    8 SHARED VOTING POWER
    0 shares
     
    9 SOLE DISPOSITIVE POWER
    715,705 shares
     
    10 SHARED DISPOSITIVE POWER
    0 shares
      
    11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    715,705 shares
     
    12

    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
    x

     

    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11);
    2.8%

     

    14

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
    PN

     

     

     

     

     

    CUSIP No. 45783Q100

     

    1

    NAME OF REPORTING PERSON.
    P2 Capital Fund IV, L.P.

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
    (a)
    ¨
    (b)
    ¨

     

    3

    SEC USE ONLY

     

    4

    SOURCE OF FUNDS (SEE INSTRUCTIONS)
    SC

     

    5

    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)
    ¨

     

    6

    CITIZENSHIP OR PLACE OF ORGANIZATION
    State of Delaware

     

    NUMBER OF
    SHARES BENEFICIALLY OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    7 SOLE VOTING POWER
    0 shares
      
    8 SHARED VOTING POWER
    0 shares
     
    9 SOLE DISPOSITIVE POWER
    0 shares
     
    10 SHARED DISPOSITIVE POWER
    0 shares
      
    11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    0 shares
     
    12

    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
    x

     

    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11);
    0%

     

    14

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
    PN

     

     

     

     

     

    CUSIP No. 45783Q100

     

    1

    NAME OF REPORTING PERSON.
    Savanna Holdings, LLC

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
    (a)
    ¨
    (b)
    ¨

     

    3

    SEC USE ONLY

     

    4

    SOURCE OF FUNDS (SEE INSTRUCTIONS)
    SC

     

    5

    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)
    ¨

     

    6

    CITIZENSHIP OR PLACE OF ORGANIZATION
    State of Delaware

     

    NUMBER OF
    SHARES BENEFICIALLY OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    7 SOLE VOTING POWER
    0 shares
      
    8 SHARED VOTING POWER
    0 shares
     
    9 SOLE DISPOSITIVE POWER
    0 shares
     
    10 SHARED DISPOSITIVE POWER
    0 shares
      
    11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    0 shares
     
    12

    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
    x

     

    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11);
    0%

     

    14

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
    CO

     

     

     

     

     

    CUSIP No. 45783Q100

     

    1

    NAME OF REPORTING PERSON.
    Claus Moller

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
    (a)
    ¨
    (b)
    ¨

     

    3

    SEC USE ONLY

     

    4

    SOURCE OF FUNDS (SEE INSTRUCTIONS)
    SC

     

    5

    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)
    ¨

     

    6

    CITIZENSHIP OR PLACE OF ORGANIZATION
    Denmark

     

    NUMBER OF
    SHARES BENEFICIALLY OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    7 SOLE VOTING POWER
    0 shares
      
    8 SHARED VOTING POWER
    779,463 shares
     
    9 SOLE DISPOSITIVE POWER
    0 shares
     
    10 SHARED DISPOSITIVE POWER
    779,463 shares
      
    11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    779,463 shares
     
    12

    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
    ¨

     

    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11);
    3.0%

     

    14

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
    IN

     

     

     

     

     

     

    EXPLANATORY NOTE

     

    This Amendment No. 1 to Schedule 13D amends and supplements the Schedule 13D filed with the Securities and Exchange Commission (the “SEC”) on November 15, 2021 (the “Original Schedule 13D”). Except as set forth herein, the Original Schedule 13D is unmodified and remains in full force and effect. Each capitalized term used but not defined herein has the meaning ascribed to such term in the Original Schedule 13D.

     

    Item 3Source and Amount of Funds or Other Consideration

     

    Item 3 is hereby amended in relevant part as follows:

     

    The information set forth in Item 5 below is incorporated herein by reference.

     

    Item 4Purpose of Transaction

     

    Item 4 is hereby amended in relevant part as follows:

     

    The information set forth in Item 5 below is incorporated herein by reference.

     

    Item 5Interest in Securities of the Issuer

     

    Item 5 is hereby amended in relevant part as follows:

     

    (a)-(b):

     

    On September 16, 2022, Savanna Holdings distributed 2,946,961 Shares to Master Fund I and Fund IV, ratably, for no consideration. In addition, on September 16, 2022 Fund IV distributed 2,231,256 Shares to its partners, ratably, for no consideration, which included 63,758 Shares distributed to P2 Capital GP IV, LLC (“GP IV”).

     

    As of the date hereof, Master Fund I holds directly 715,705 Shares, representing 2.8% of the outstanding Shares and Fund IV no longer holds any Shares. The Manager, as investment manager of the Funds, and Claus Moller, as managing member of the Manager, may each be deemed to own beneficially all Shares that are held directly by the Funds. Each of the Manager and Mr. Moller disclaims beneficial ownership of the Shares held directly by the Funds for all other purposes.

     

    Mr. Moller is also the managing member of GP IV and may be deemed to own beneficially all Shares that are held directly by GP IV. Mr. Moller disclaims beneficial ownership of the Shares held directly by GP IV for all other purposes.

     

    The percentages of beneficial ownership in this Schedule 13D are based on an aggregate of 25,593,313 Shares outstanding, based on the number of Shares outstanding as of August 3, 2022 as reported in the Issuer’s Quarterly Report on Form 10-Q filed on August 12, 2022.

     

    Following the distributions described above, Savanna Holdings no longer holds any Shares and is no longer subject to the voting arrangements under the Shareholders Agreement. As a result, the Reporting Persons are no longer deemed to constitute a “group” with Jermyn Street and the other shareholders party to the Shareholders Agreement for purposes of section 13(d) of the Securities Exchange Act of 1934, as amended.

     

    (c) Except as set forth in Item 5, none of the Reporting Persons has engaged in any transaction during the past 60 days in any Shares.

     

    (e) As of September 16, 2022, each of the Reporting Persons ceased to be a beneficial owner of more than five percent of the outstanding Shares.

     

    Item 6Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer

     

    Item 6 is hereby amended by adding the following paragraph after paragraph four of “Shareholders Agreement”:

     

    As a result of the distributions described in Item 5 above, Savanna Holdings no longer satisfies the minimum ownership threshold set forth in the Shareholders Agreement to designate any members to the Issuer’s board of directors. Savanna Holdings also no longer has any voting rights or obligations and any registrations rights with respect to the Issuer’s Shares.

     

     

     

     

    Item 7Material to Be Filed as Exhibits

     

    Exhibit Description
         
    1 Joint Filing Agreement, dated as of September 20, 2022, among Savanna Holdings, LLC, P2 Capital Master Fund I, L.P., P2 Capital Fund IV, L.P., P2 Capital Partners, LLC, and Claus Moller.

     

     

     

     

    Signature

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: September 20, 2022

     

    Savanna Holdings, LLC By: P2 Capital Master Fund I, L.P., as Managing Member
      By: P2 Capital Partners, LLC, as Investment Manager
         
      /s/ Claus Moller
      Name: Claus Moller
      Title: Managing Member
         
    P2 Capital Master Fund I, L.P. By: P2 Capital Partners, LLC, as Investment Manager
         
      /s/ Claus Moller
      Name: Claus Moller
      Title: Managing Member

     

    P2 CapiTal Fund IV, L.P. By: P2 Capital Partners, LLC, as Investment Manager

     

      /s/ Claus Moller
      Name: Claus Moller
      Title: Managing Member

     

    P2 Capital Partners, LLC /s/ Claus Moller
      Name: Claus Moller
      Title: Managing Member

     

    CLAUS MOLLER /s/ Claus Moller

     

     

     

    Get the next $NOTV alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NOTV

    DatePrice TargetRatingAnalyst
    5/14/2024$11.50 → $3.75Buy → Hold
    Jefferies
    2/9/2024$3.00 → $11.50Hold → Buy
    Jefferies
    7/20/2023$9.00Overweight
    Wells Fargo
    1/19/2023$10.00 → $8.00Buy → Hold
    Jefferies
    1/11/2023$4.00 → $10.00Hold → Buy
    Lake Street
    11/18/2022$60.00 → $7.00Buy → Hold
    Lake Street
    10/4/2022$27.00Buy
    Jefferies
    1/31/2022$60.00Buy
    Lake Street
    More analyst ratings

    $NOTV
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Inotiv Reports Second Quarter Financial Results for Fiscal 2025 and Provides Business Update

      —  Second quarter fiscal 2025 revenue increased 4.4% to $124.3 million—  Year-to-date fiscal 2025 revenue declined 4.1% to $244.2 million—  Conference call scheduled for today at 4:30 pm ET WEST LAFAYETTE, Ind., May 07, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the "Company"), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced financial results for the three months ("Q2 FY 2025") ended March 31, 2025 and six months ("YTD FY 2025") ended March 31, 2025. Revenue by Segment (in millions of USD)   Three Months EndedMarch 31, %change Six Mo

      5/7/25 4:05:00 PM ET
      $NOTV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Inotiv, Inc. to Report Fiscal 2025 Second Quarter Financial Results and Host Conference Call on Wednesday, May 7, 2025

      WEST LAFAYETTE, Ind., April 23, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the "Company", or "Inotiv"), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2025 second quarter ended March 31, 2025, on Wednesday, May 7, 2025, after the close of the stock market. The Company will host a conference call that same day at 4:30 p.m. Eastern Time to discuss the results. Interested parties may participate in the call by dialing: 1-800-245-3047 (Domestic)1-203-518-9765 (International)INOTIV

      4/23/25 4:05:00 PM ET
      $NOTV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Inotiv Reports First Quarter Financial Results for Fiscal 2025 and Provides Business Update

      Enhanced liquidity by $27.5 million through the issuance of 6.9 million common sharesFirst quarter fiscal 2025 revenue declined 11.5% to $119.9 millionConference call scheduled for today at 4:30 pm ET WEST LAFAYETTE, Ind., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the "Company"), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced financial results for the three months ("Q1 FY 2025") ended December 31, 2024. Revenue by Segment (in millions of USD)  Three Months EndedDecember 31, % change   2024  2023    (unaudite

      2/5/25 4:05:00 PM ET
      $NOTV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $NOTV
    Leadership Updates

    Live Leadership Updates

    See more
    • Universal Display Corporation Announces the Appointment of New Board Members

      Universal Display Corporation (NASDAQ:OLED) (UDC), enabling energy-efficient displays and lighting with its UniversalPHOLED® technology and materials, today announced that Dr. Nigel Brown and Dr. Joan Lau have joined the Company's Board of Directors, effective March 4, 2024. The addition of these new directors expands UDC's Board to ten members. "I am pleased to welcome Nigel and Joan to the Board," said Steven V. Abramson, President and Chief Executive Officer of Universal Display Corporation and a member of the Board. "Nigel adds a wealth of business innovation, technical knowledge and corporate strategic planning expertise to our Board. Joan brings over two decades of extensive scienti

      3/7/24 4:05:00 PM ET
      $BDN
      $NOTV
      $OLED
      $RMTI
      Real Estate Investment Trusts
      Real Estate
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Inotiv, Inc. Announces Changes to its Board Composition

      WEST LAFAYETTE, Ind., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV), a leading contract research organization, today announced the appointment of Terry Coelho to its Board of Directors. Ms. Coelho is replacing Richard A. Johnson PhD, who is leaving the Board as part of the Board's succession planning. Ms. Coelho was also appointed to serve as a member of the Compensation Committee and the Audit Committee, and as a member and the Chair of the Nominating/Corporate Governance Committee of the Board. Ms. Coelho is the CFO at Gamida Cell Ltd., a public, commercial stage biotech company. Previously, Ms. Coelho was Executive Vice President, CFO and Chief Business Development Offic

      10/16/23 8:00:00 AM ET
      $NOTV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $NOTV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Inotiv Inc. (Amendment)

      SC 13D/A - Inotiv, Inc. (0000720154) (Subject)

      4/3/24 10:47:10 AM ET
      $NOTV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SC 13D/A filed by Inotiv Inc. (Amendment)

      SC 13D/A - Inotiv, Inc. (0000720154) (Subject)

      10/6/22 12:24:15 PM ET
      $NOTV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SC 13D/A filed by Inotiv Inc. (Amendment)

      SC 13D/A - Inotiv, Inc. (0000720154) (Subject)

      9/20/22 9:00:08 AM ET
      $NOTV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $NOTV
    SEC Filings

    See more
    • SEC Form 10-Q filed by Inotiv Inc.

      10-Q - Inotiv, Inc. (0000720154) (Filer)

      5/7/25 8:28:27 PM ET
      $NOTV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Inotiv Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Inotiv, Inc. (0000720154) (Filer)

      5/7/25 4:10:58 PM ET
      $NOTV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Inotiv Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Inotiv, Inc. (0000720154) (Filer)

      3/13/25 4:50:23 PM ET
      $NOTV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $NOTV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Landman David bought $99,998 worth of shares (23,529 units at $4.25), increasing direct ownership by 15% to 176,851 units (SEC Form 4)

      4 - Inotiv, Inc. (0000720154) (Issuer)

      12/23/24 9:47:13 PM ET
      $NOTV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Chief Operating Officer Beattie John Gregory bought $142,500 worth of shares (30,000 units at $4.75), increasing direct ownership by 23% to 161,761 units (SEC Form 4)

      4 - Inotiv, Inc. (0000720154) (Issuer)

      12/12/24 6:46:46 PM ET
      $NOTV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Director Brown Nigel bought $31,950 worth of shares (7,500 units at $4.26), increasing direct ownership by 13% to 65,537 units (SEC Form 4)

      4 - Inotiv, Inc. (0000720154) (Issuer)

      12/10/24 4:13:30 PM ET
      $NOTV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $NOTV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Coelho Mary Theresa sold $12,916 worth of shares (5,500 units at $2.35), decreasing direct ownership by 7% to 74,303 units (SEC Form 4)

      4 - Inotiv, Inc. (0000720154) (Issuer)

      4/2/25 4:32:56 PM ET
      $NOTV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • President and CEO Leasure Robert Jr. was granted 429,730 shares, increasing direct ownership by 45% to 1,386,322 units (SEC Form 4)

      4 - Inotiv, Inc. (0000720154) (Issuer)

      3/18/25 5:39:56 PM ET
      $NOTV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Director Neff R Matthew was granted 39,392 shares, increasing direct ownership by 34% to 155,102 units (SEC Form 4)

      4 - Inotiv, Inc. (0000720154) (Issuer)

      3/18/25 4:15:52 PM ET
      $NOTV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $NOTV
    Financials

    Live finance-specific insights

    See more
    • Inotiv Reports Second Quarter Financial Results for Fiscal 2025 and Provides Business Update

      —  Second quarter fiscal 2025 revenue increased 4.4% to $124.3 million—  Year-to-date fiscal 2025 revenue declined 4.1% to $244.2 million—  Conference call scheduled for today at 4:30 pm ET WEST LAFAYETTE, Ind., May 07, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the "Company"), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced financial results for the three months ("Q2 FY 2025") ended March 31, 2025 and six months ("YTD FY 2025") ended March 31, 2025. Revenue by Segment (in millions of USD)   Three Months EndedMarch 31, %change Six Mo

      5/7/25 4:05:00 PM ET
      $NOTV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Inotiv, Inc. to Report Fiscal 2025 Second Quarter Financial Results and Host Conference Call on Wednesday, May 7, 2025

      WEST LAFAYETTE, Ind., April 23, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the "Company", or "Inotiv"), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2025 second quarter ended March 31, 2025, on Wednesday, May 7, 2025, after the close of the stock market. The Company will host a conference call that same day at 4:30 p.m. Eastern Time to discuss the results. Interested parties may participate in the call by dialing: 1-800-245-3047 (Domestic)1-203-518-9765 (International)INOTIV

      4/23/25 4:05:00 PM ET
      $NOTV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Inotiv, Inc. to Report Fiscal 2025 First Quarter Financial Results and Host Conference Call on Wednesday, February 5, 2025

      WEST LAFAYETTE, Ind., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the "Company", or "Inotiv"), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2025 first quarter ended December 31, 2024, on Wednesday, February 5, 2025, after the close of the stock market. The Company will host a conference call that same day at 4:30 p.m. Eastern Time to discuss the results. Interested parties may participate in the call by dialing: 1-800-579-2543 (Domestic)1-785-424-1789 (International)I

      1/22/25 4:05:00 PM ET
      $NOTV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $NOTV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Inotiv downgraded by Jefferies with a new price target

      Jefferies downgraded Inotiv from Buy to Hold and set a new price target of $3.75 from $11.50 previously

      5/14/24 8:01:45 AM ET
      $NOTV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Inotiv upgraded by Jefferies with a new price target

      Jefferies upgraded Inotiv from Hold to Buy and set a new price target of $11.50 from $3.00 previously

      2/9/24 6:17:55 AM ET
      $NOTV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Wells Fargo initiated coverage on Inotiv with a new price target

      Wells Fargo initiated coverage of Inotiv with a rating of Overweight and set a new price target of $9.00

      7/20/23 7:55:03 AM ET
      $NOTV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care